Capillary Ketone Level and Future Ketoacidosis Risk in Patients With Type 1 Diabetes Using Sodium-Glucose Cotransporter Inhibitors.
第1型糖尿病患者使用Sodium-Glucose Cotransporter抑制劑時,微血管酮體水平與未來酮酸中毒風險之關聯
Diabetes Care 2025-04-23
Chronic treatment with SGLT-2 inhibitors is associated with ICU admission and disease severity in patients with diabetic ketoacidosis: a propensity score-matched cohort study.
慢性使用 SGLT-2 抑制劑與糖尿病酮症酸中毒患者的重症監護室入院及疾病嚴重程度相關:一項傾向得分匹配的隊列研究。
Intern Emerg Med 2024-11-18
Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
1型糖尿病患者使用鈉葡萄糖共轉運蛋白-2抑制劑引起糖尿病酮症酸中毒的風險:隨機對照試驗的系統評價和網絡Meta分析。
Front Endocrinol (Lausanne) 2025-02-17
Sodium-Glucose Cotransporter-2 Inhibitors and Diabetic-Ketoacidosis in T2DM Patients: An Updated Meta-Analysis and a Mendelian Randomization Analysis.
鈉-葡萄糖共轉運蛋白-2 抑制劑與 2 型糖尿病患者的糖尿病酮症酸中毒:更新的統合分析及孟德爾隨機化分析。
Clin Pharmacol Ther 2025-03-12
Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial.
dapagliflozin 對於 1 型糖尿病成人在監督下胰島素撤回期間血液和呼吸酮體的影響:一項隨機交叉試驗。
Diabetes Obes Metab 2025-03-14
Clinical use and monitoring of adverse effects of sodium-glucose cotransporter-2 inhibitors in persons with type 1 diabetes mellitus.
第1型糖尿病患者使用SGLT2抑制劑的臨床應用與不良反應監測
J Diabetes Investig 2025-05-26
Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes. Part B: Risks of sodium-glucose co-transporter inhibitor use in type 1 diabetes and ketoacidosis risk mitigation strategies.
重新檢視鈉-葡萄糖共轉運蛋白抑制劑於第一型糖尿病中的效益與風險概況。B 部分:鈉-葡萄糖共轉運蛋白抑制劑於第一型糖尿病中的風險及酮酸中毒風險緩解策略
Diabetes Res Clin Pract 2025-05-29